Z
10.33
-0.99 (-8.75%)
| Previous Close | 11.32 |
| Open | 11.20 |
| Volume | 171,672 |
| Avg. Volume (3M) | 198,330 |
| Market Cap | 473,563,360 |
| Price / Sales | 31.56 |
| Price / Book | 1.67 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2025 |
| Operating Margin (TTM) | -373.30% |
| Diluted EPS (TTM) | -3.55 |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 6.47 |
| Operating Cash Flow (TTM) | -137.62 M |
| Levered Free Cash Flow (TTM) | -77.73 M |
| Return on Assets (TTM) | -56.70% |
| Return on Equity (TTM) | -115.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Zenas BioPharma, Inc. | Bearish | - |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.20% |
| % Held by Institutions | 74.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Enavate Sciences Gp, Llc | 31 Mar 2025 | 3,761,359 |
| Novo Holdings A/S | 31 Mar 2025 | 2,214,967 |
| Fairmount Funds Management Llc | 31 Mar 2025 | 1,892,806 |
| Nvp Associates, Llc | 31 Mar 2025 | 1,838,482 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Wedbush, 238.82%) | Buy |
| Median | 32.50 (214.62%) | |
| Low | 30.00 (HC Wainwright & Co., 190.42%) | Buy |
| Average | 32.50 (214.62%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 May 2025 | 30.00 (190.42%) | Buy | 10.47 |
| Wedbush | 20 Mar 2025 | 35.00 (238.82%) | Buy | 8.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |